Posts Tagged 'malaria'

How the malaria vaccine works…

March 2009 — 15,460 children are enrolled in a unique vaccine study. The study, encompassing seven African countries, was the first of its kind to test the efficacy of a vaccine against a parasitic-borne disease. That in itself was something many thought would never be seen.

Yesterday — October 18th — the results of that study, the largest ever malaria study, was published in the New England Journal of Medicine, spelling out new hope for fighting a disease that accounts for 800,000 lives lost on a yearly basis – most of them children under the age of 5.

The vaccine, that has been in development for the better part of two decades — the interestingly titled RTS,S – provided protection against both clinical and severe malaria in African children. RTS,S was designed as a vaccine to prevent malaria infection, but it has proven to prevent clinical and severe disease. The trial was a randomized, controlled, and doubleblind designed to evaluate vaccine efficacy, safety, reactogenicity, and immunogenicity in children up to 32 months after the administration of the first dose.

From the abstract:

“In the 14 months after the first dose of vaccine, the incidence of first episodes of clinical malaria in the first 6000 children in the older age category was 0.32 episodes per person-year in the RTS,S/AS01 group and 0.55 episodes per person-year in the control group, for an efficacy of 50.4% (95% confidence interval [CI], 45.8 to 54.6) in the intention-to-treat population and 55.8% (97.5% CI, 50.6 to 60.4) in the per-protocol population. Vaccine efficacy against severe malaria was 45.1% (95% CI, 23.8 to 60.5) in the intention-to-treat population and 47.3% (95% CI, 22.4 to 64.2) in the per-protocol population. Vaccine efficacy against severe malaria in the combined age categories was 34.8% (95% CI, 16.2 to 49.2) in the per-protocol population during an average follow-up of 11 months. Serious adverse events occurred with a similar frequency in the two study groups. Among children in the older age category, the rate of generalized convulsive seizures after RTS,S/AS01 vaccination was 1.04 per 1000 doses (95% CI, 0.62 to 1.64).”

It should be stressed that no one is viewing this new vaccine as the miracle drug or the silver bullet for this disease. Far from it. Researchers are right to point out “A malaria vaccine, deployed in combination with current malaria-control tools, could play an important role in future control and eventual elimination of malaria in Africa”.

Just another weapon in the armoury in the fight against the disease. Indeed, none of the malaria vaccines in various stages of the development process have shown anywhere near 100% efficacy.

RTS,S is the most advanced vaccine candidate against malaria to date, and the story of RTS,S is not just a story of how much we know and understand disease, but also how much we don’t know. The landmarks and feats that went in to getting a workable vaccine for malaria is one done in spite of the gaps in our knowledge. The questions left unanswered offer an important starting point and challenge in the quest to understand the protection afforded by RTS,S and to build a more efficacious second generation vaccine against malaria.

The malaria parasite has a complex life cycle. One that is needed to be understood to understand the vaccine.The life cycle of the malaria parasite starts with the bite of an infected mosquito (female anopholese), inoculating sporozoites into the human host. Within the host it is complex, consisting of  an asymptomatic liver stage (pre-erythrocytic) infection followed by a symptomatic blood stage (erythrocytic) infection. Sporozoites infect liver cells and mature into schizonts. The liver cell ruptures releasing merozoites, which infect red blood cells.

The parasite’s life cycle within the liver is very short. At one point it was thought that a vaccine against the liver stage would prove too ineffective, as immune responses induced by vaccination against liver stage parasites could not act quickly enough to destroy the infected liver cells (hepatocytes) and to prevent the release of liver-stage parasites (merozoites) into the blood.

“During its remarkable journey from conception and design in the early 1980s to the multicenter Phase 3 trial currently underway across sub-Saharan Africa, RTS,S has overcome tremendous challenges and disproved established vaccine paradigms.”

For the sake of brevity, the story of a malaria vaccine begins its life in the 1960s. Researchers at New York University demonstrated that immunization of animals with the bites of irradiated-attenuated infected mosquitoes could protect against infectious sporozoites (the form of the parasite the mosquito injects when it bites). It was this demonstration that led to the identification of the Plasmodium falciparum circumsporozoite (CS) protein expressed on sporozoites  and liver stage schizonts – the basis of the RTS,S vaccine we have today.

The CS protein is present in large amounts on the surface of sporozoites and is also expressed by liver schizonts. The modestly sized CS protein is one involved in sporozoite invasion of mosquito salivary glands as well as in binding to hepatocytes prior to invasion of the liver cells.

The pertinent question is how the vaccine confers immunity, given the very small window of opportunity in which the parasite is exposed.

“immunity conferred by the RTS,S vaccine could act by attacking sporozoites during the short time in which they are in the circulation, disabling them and preventing them from invading liver cells, or by attacking liver schizonts.”

The short answer is we don’t really know. The even shorter answer is that we may never really know, as identification of an immunological measurement that provides a reliable measure of clinical protection in RTS-vaccinated individuals from all populations might never be possible.

RTS,S candidate malaria vaccines induce very high titres of anti-circumsporozoite antibodies as well as a strong CD4 T-cell response (characterised by the production of inflammatory cytokines such as interferon γ), which could contribute to the killing of the liver schizonts.

The chemistry of the vaccine itself is more concrete. The vaccine antigen consists of 19 copies of the central tandem repeats and C-terminal region of the CS protein fused to hepatitis B surface antigen (HBsAg), and co-expressed with unfused HBsAg in Saccharomyces cerevisiae cells.

In order to prevent allergic reactions and autoimmunity, the immune system is generally tolerant to antigens, unless antigens trigger “danger signals” that mobilize the immune system to react aggressively. This is the basis of adjuvant systems. Adjuvants have been long known for their ability to trigger danger signals and have been widely used for immunization purposes. The RTS,S adjuvant comes in two flavours (out of 11 possible different formulations tested) — AS02 and AS01.

The general requirement for an adjuvant formulation (among others) is to stabilize antigen and slow its release to the immune system. AS02 is a squalene-in-water emulsion containing MPL (monophosphoril lipid A), and a saponin (triterpene glycoside) derived from the bark of the plant Quillaja saponaria (QS21). QS21 is thought to function to trap components of the vaccine formulation through hydrophobic interactions and thereby slows their release to the immune system. MPL is a derivative of a lipopolysaccharide that triggers danger signals in macrophages and dendritic cells, and promotes secretion of pro-inflammatory cytokines.

AS01b was developed to increase immunogenicity, in which the oil-in-water emulsion of AS02 was replaced by liposomes. The liposomes replacement meant that RTS,S is delivered to the trans-Golgi in antigen-presenting cells, where the RTS,S is efficiently processed and enhances MHC class I and class II antigen presentation to T cells.

The protection conferred by RTS,S vaccine does not seem to be strain specific. A valid concern is that there is a possibility that RTS,S vaccination could lead to the emergence of a P. falciparum parasite strains carrying polymorphisms in the CS protein. However, some recent trials have shown no increase in the frequency of genetically variant parasites in vaccinated groups.

All in all the RTS,S vaccine is the spark of promise and hope in controlling a disease that causes so much human death and suffering. But it is by no means that last word. As it’s often said, the miracle drug will always be a hard pill to swallow. In the case of diseases of the world’s poorest, there is the problem that the miracle drug will always be one too expensive. More funding will be needed to understand more about this vaccine’s efficacy, the duration of protection, and how best to implement this vaccine to most effectively to control malaria.

The RTS,S malaria vaccine
First Results of Phase 3 Trial of RTS,S/AS01 Malaria Vaccine in African Children
Immunological correlates of protection for the RTS,S candidate malaria vaccine

War and other drugs…

War, for all its ills and wrongs, has always been a force for progress. Technological and sometimes otherwise. Men on the moon, radar, space shuttles, nuclear energy, airplanes. The poison gases of the first world war and the Manhattan project of the second. Rockets, cryptography, meteorology.

Early American history provides a good example, not of technological progress, but of foresight. General Washington, believing that disease was far deadlier than the “sword of the enemy”, ordered his troops to be inoculated for smallpox during the revolutionary war. The original hand-written letter is on display for all to see. That letter reduced smallpox mortality from 17% to 1%, and most likely helped fight off the British army.

The question on the other side of treatment is always diagnosis. How to diagnose specific parasitic and microbiological infections in a war setting. Deployed troops mandate the same standard of healthcare no matter where they are. And this can often be a problem as manpower and technical expertise are in short supply. The German army, like many others, implement telemedicine as a solution to this problem. Laboratory-based diagnosis and rapid access to state-of-the-art techniques of infectious diseases is necessary at all levels of military health service. In the past, the time-consuming transportation of specimens to Germany was the only mechanism available to make high quality microbiological expertise available in support of missions abroad. Now remote-support is proving a vital tool. Distinguishing between a malaria infection caused by Plasmodium vivax and one caused by Plasmodium falciparum can now be done remotely and with great detail, transmitting images via satellite quickly to a home base hospital back in Germany staffed round the clock. Telemedicine is just one small part of the ICT revolution currently sweeping the global health world.

Infectious diseases are among the most common medical conditions suffered by soldiers while serving in missions away. For centuries the death toll from war has alays been made worse by disease. Consider the scence at the end of H.G. Wells’ “The War of the Worlds” when invading alien forces succumbs to a common infection to which they have no immunity.

We know that the wars in Europe and Vietnam led to the development of chloroquine, mefloquine and halofantrine for malaria. In 1967, Chinese scientists set up Project 523 – a secret military project, named after the date (23 May 1967). The intention was to help the Vietnamese military defeat malaria by developing an antimalarial.

“Following orders, my comrades and I travelled along the Beibu (Tonkin) Gulf and through the Ho Chi Minh Trail in the jungle – it was the only way to maintain supplies for North Viet Nam because the United States of America had bombed it so intensely. We were accompanied by showers of bombs during the trip. There, I witnessed rampant malaria that reduced the combat strength by half, sometimes by up to 90% when the soldiers became ill. There was a saying, “We’re not afraid of American imperialists, but we are afraid of malaria,” although in fact the disease took a huge toll on both sides.”

And, thus, artemisinin was born. Zhou Yiqing, the lead scientist on the project, tells the story of artemisinin research — from its early inception, it getting noticed in the western world, to its now widespread use to combat malaria around the world.

Telemicrobiology: a novel telemedicine capability for mission support in the field of infectious medicine
Telemed J E Health. 2007 Apr;13(2):108-17.

What had I twaught…

%d bloggers like this: